Global Antisense & RNAi Therapeutics Market Research Report 2022: Analysis of Oncology, Cardiovascular Diseases, Respiratory Disorders, Neurological Disorders, & Infectious Diseases
21 juin 2022 04h23 HE | Research and Markets
Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Global Market Report 2022: By Technology, By Route, By Indication" report has been added to ResearchAndMarkets.com's...
TIP_link_300x300.jpg
Genome Editing Market Size ($16.98Bn by 2028) Lead by CRISPR Technology (18.4% CAGR) - Exclusive Research Report by The Insight Partners
20 janv. 2022 12h48 HE | The Insight Partners
New York, Jan. 20, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN,...
22157.jpg
$11.7 Bn Genome Editing/Genome Engineering Markets - Global Analysis & Forecasts to 2026
20 déc. 2021 05h28 HE | Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Genome Editing/Genome Engineering Market - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global genome...
22157.jpg
Global RNA Targeting Small Molecules Therapeutics Market Research Report 2021 with Analysis & Forecasts to 2030
09 nov. 2021 06h18 HE | Research and Markets
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RNA Targeting Small Molecules Therapeutics Market by Type of Target Molecule, Type of Approach, Target Indication, Target Therapeutic Area, Route of...
22157.jpg
Antisense Oligonucleotide Therapeutics Pipeline Insight Report 2021: Focus on 15+ Companies and 15+ Pipeline Drugs
18 oct. 2021 11h23 HE | Research and Markets
Dublin, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This "Antisense...
ProgenityLogo.jpg
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
21 sept. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership...
ProgenityLogo.jpg
Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies
06 avr. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Antisense Therapeutics to Present at Rodman & Renshaw 11th Annual Healthcare Conference
31 août 2009 10h39 HE | Antisense
MELBOURNE, AUSTRALIA--(Marketwire - August 31, 2009) - Antisense Therapeutics Limited (PINKSHEETS: ATHJY) (ASX: ANP) today announced that the Company is scheduled to present at the Rodman &...